Biogen Inc.: Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

CAMBRIDGE, Mass., March 11, 2022(Nasdaq: BIIB) announced the company will present new Alzheimer's disease research, as well as data for ADUHELM (aducanumab-avwa) injection 100 mg/mL for intravenous use

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Ashleigh Koss ,Mike Hencke ,Walter Gilbert ,Charles Weissmann ,Heinz Schaller ,Kenneth Murray ,Linkedin ,Twitter ,International Conference On Alzheimer ,Nasdaq ,Eisai Co Ltd ,Exchange Commission ,Youtube ,Facebook ,International Conference ,Amyloid Levels ,Cognitive Decline ,Randomized Clinical Trials ,Global Statistical Tests ,Symptom Progression ,Treatment Response ,Early Alzheimer ,Trials Evaluating Aducanumab ,Exposure Response Analysis Evaluating ,Relationship Between Amyloid Removal ,Clinical Decline ,Amyloid Related Imaging Abnormalities ,Prescribing Information ,Medication Guide ,Sir Kenneth Murray ,Nobel Prize ,Healthy Lives ,Private Securities Litigation Reform Act ,Biogen ,Present ,Research ,Nternational ,Conference ,Lzheimer ,Parkinson ,Diseases ,022 ,